The elevated levels of LRRC15-positive CAFs signatures correlated with poor responses to anti-PD-L1 therapy, and the depletion of LRRC15-positive CAFs markedly reduced the total tumor fibroblast content [23], which relieves the direct suppression of CTLs (Figure 2) and augments tumor regression. Here, LRRC15 is linked to neoplasm.